CA2308513A1 - Method and composition for delivering zinc to the nasal membrane - Google Patents

Method and composition for delivering zinc to the nasal membrane Download PDF

Info

Publication number
CA2308513A1
CA2308513A1 CA002308513A CA2308513A CA2308513A1 CA 2308513 A1 CA2308513 A1 CA 2308513A1 CA 002308513 A CA002308513 A CA 002308513A CA 2308513 A CA2308513 A CA 2308513A CA 2308513 A1 CA2308513 A1 CA 2308513A1
Authority
CA
Canada
Prior art keywords
composition
nasal membrane
delivering zinc
delivering
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002308513A
Other languages
French (fr)
Other versions
CA2308513C (en
Inventor
Charles Hensley
Robert Steven Davidson
Gary S. Kehoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zicam LLC
Original Assignee
Charles Hensley
Robert Steven Davidson
Gary S. Kehoe
Gel Tech, L.L.C.
Zicam, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22511336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2308513(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Charles Hensley, Robert Steven Davidson, Gary S. Kehoe, Gel Tech, L.L.C., Zicam, Llc filed Critical Charles Hensley
Publication of CA2308513A1 publication Critical patent/CA2308513A1/en
Application granted granted Critical
Publication of CA2308513C publication Critical patent/CA2308513C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.
CA002308513A 1998-09-01 1999-09-01 Method and composition for delivering zinc to the nasal membrane Expired - Fee Related CA2308513C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/145,042 US6080783A (en) 1998-09-01 1998-09-01 Method and composition for delivering zinc to the nasal membrane
US09/145,042 1998-09-01
PCT/US1999/020185 WO2000012081A1 (en) 1998-09-01 1999-09-01 Method and composition for delivering zinc to the nasal membrane

Publications (2)

Publication Number Publication Date
CA2308513A1 true CA2308513A1 (en) 2000-03-09
CA2308513C CA2308513C (en) 2005-01-04

Family

ID=22511336

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002308513A Expired - Fee Related CA2308513C (en) 1998-09-01 1999-09-01 Method and composition for delivering zinc to the nasal membrane

Country Status (9)

Country Link
US (8) US6080783A (en)
EP (1) EP1039896A4 (en)
JP (2) JP2002523453A (en)
KR (1) KR100439323B1 (en)
CN (1) CN1293869C (en)
AU (1) AU774410B2 (en)
BR (1) BR9906758A (en)
CA (1) CA2308513C (en)
WO (1) WO2000012081A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
US20050232868A1 (en) * 1999-10-19 2005-10-20 The Procter & Gamble Company Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
US20040234457A1 (en) * 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
AU2002239801A1 (en) * 2000-10-27 2002-06-03 Pearl Street Financial Group Ltd. Debt financing for companies
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20030215491A1 (en) * 2001-04-30 2003-11-20 Hensley Charles B. Method and composition for rapid delivery of bioactive compounds to the systemic circulation via the nasal membrane
MXPA04003359A (en) * 2001-10-12 2004-11-29 Cns Corporated Hydrating nasal gel and applicator.
US8679462B2 (en) * 2002-04-11 2014-03-25 Saeed Rezakhany Methods of preventing respiratory infections
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
WO2004011017A1 (en) * 2002-07-31 2004-02-05 Himalayan International Institute Of Yoga Science And Philosophy Nasal irrigation solutions and methods of using same
AU2003272517A1 (en) * 2002-09-13 2004-04-30 Zicam, Llc. Compositions to reduce congestion and methods for application thereof to the nasal membrane
WO2004024225A1 (en) 2002-09-16 2004-03-25 Zicam, Llc. System and method for delivering a composition to the nasal membrane
DE10358372A1 (en) * 2003-04-03 2004-10-14 Basf Ag Trimethylolpropane esters are useful for the production of cross-linked hydrogels, useful for the production of hygiene articles, packaging materials and non-wovens
US20070092583A1 (en) * 2003-04-30 2007-04-26 Tim Clarot Cold remedy composition comprising zinc salts
US8216171B2 (en) * 2003-07-15 2012-07-10 Deka Products Limited Partnership Individual dose packaging
US20050043253A1 (en) * 2003-08-19 2005-02-24 Cook Bradley R. Use of wound healing compositions for prevention of infections and allergies
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
ITMI20040235A1 (en) * 2004-02-13 2004-05-13 Therapicon Srl PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE
EP1819222A2 (en) * 2004-12-09 2007-08-22 The Dial Corporation Compositions having a high antiviral and antibacterial efficacy
US20090012174A1 (en) * 2004-12-09 2009-01-08 The Dial Corporation Compositions Having a High Antiviral and Antibacterial Efficacy
WO2006062857A2 (en) * 2004-12-09 2006-06-15 The Dial Corporation Compositions having a high antiviral and antibacterial efficacy
US20080095814A1 (en) * 2004-12-09 2008-04-24 The Dial Corporation Compositions Having a High Antiviral and Antibacterial Efficacy
MX2007006862A (en) * 2004-12-09 2008-02-15 Dial Corp Compositions having a high antiviral and antibacterial efficacy.
US20070135377A1 (en) * 2004-12-10 2007-06-14 Roman Stephen B Thixotropic anti-viral formulation
US20090076132A1 (en) * 2005-03-11 2009-03-19 Gary Pekoe Antiviral compositions and methods of treatment
US20070009443A1 (en) * 2005-07-05 2007-01-11 Hensley Charles B Method for inhibiting occupation by rhinovirus of cell in the nasal membrane
US20070111964A1 (en) * 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
US20070110676A1 (en) * 2005-11-17 2007-05-17 The Procter & Gamble Company Compositions useful for prevention and treatment of common cold and influenza-like symptoms
EP2040543A2 (en) * 2006-05-24 2009-04-01 The Dial Corporation Composition and method for controlling the transmission of noroviruses
MX2008015088A (en) * 2006-05-26 2009-03-05 Dial Corp Method of inhibiting the transmission of viruses.
WO2007142919A2 (en) 2006-05-30 2007-12-13 The Dial Corporation Compositions having a high antiviral effeicacy
EP2034831A2 (en) * 2006-05-31 2009-03-18 The Dial Corporation Alcohol-containing antimicrobial compositions having improved efficacy
RU2431961C2 (en) 2006-06-02 2011-10-27 Дзе Дайл Корпорейшн Method of inhibiting transfer of influenza virus
EP2046120A2 (en) * 2006-06-05 2009-04-15 The Dial Corporation Methods and articles having a high antiviral and antibacterial efficacy
WO2008037470A1 (en) * 2006-09-27 2008-04-03 Niconovum Ab Directional use
DE102007045368A1 (en) * 2007-09-22 2009-04-02 Zf Friedrichshafen Ag Method and device for lubricating the axial starts of idler gears arranged on a shaft
WO2009099405A2 (en) * 2008-01-30 2009-08-13 Dalos, Llc Antibacterial compositions and methods of treatment
US8241236B2 (en) * 2008-03-21 2012-08-14 Y B Innovations, Llc Apparatus for cleaning a nasal cavity
GB2460815A (en) * 2008-04-04 2009-12-16 Kays Medical A sterilisable gel formulation comprising calcium gluconate
US8173183B2 (en) 2008-07-02 2012-05-08 Carmell Hergert Mucosal membrane healant and moisturizer
US20100021563A1 (en) * 2008-07-24 2010-01-28 Paul Levesque Compositions comprising coconut oil and methods of use thereof
BR112012012945A2 (en) 2009-11-25 2020-12-29 Arisgen Sa MUCOSAL RELEASE COMPOSITION, ITS PRODUCTION METHOD, PRE-FORMED PEPTIDE COMPLEX, KIT AND USE OF AN ACTIVE PEPTIDE AGENT
WO2012119102A2 (en) * 2011-03-03 2012-09-07 Cearna Inc. Homeopathic therapeutic method and compositions
US10022335B2 (en) 2011-03-03 2018-07-17 Nancy Josephine Polich Homeopathic therapeutic method and compositions
US9034401B1 (en) 2014-01-23 2015-05-19 Matrixx Initiatives, Inc. Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same
CA2992352C (en) * 2015-07-14 2023-06-27 Marinomed Biotech Ag Stuffy nose deblocking composition having antiviral activity
KR20180120204A (en) 2016-02-25 2018-11-05 어플라이드 바이올로지컬 래버러토리즈 인코포레이티드 Compositions and methods for protecting airborne pathogens and stimulants
KR101825041B1 (en) * 2016-04-07 2018-02-02 주식회사 바이오솔루션 Skin External composition for treating a wound comprising substance P
JOP20190148A1 (en) * 2016-12-21 2019-06-18 Bayer Pharma AG Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
KR20200139170A (en) * 2018-04-06 2020-12-11 필립모리스 프로덕츠 에스.에이. Nicotine gel
FR3113237B1 (en) * 2020-08-04 2023-06-09 Biopass PRODUCT FOR THE TREATMENT OF VIRAL DISEASES BY NASAL WAY
CA3188053A1 (en) * 2020-08-04 2022-02-10 Stephanie Audran Hydrogel comprising glycerol and a carbomer for treating the respiratory symptoms of covid-19 disease via the nasal route

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965908A (en) * 1975-01-02 1976-06-29 Posthuma Albert E Synthetic physiological mucus
US5002970A (en) 1981-07-31 1991-03-26 Eby Iii George A Flavor masked ionizable zinc compositions for oral absorption
US4503070A (en) 1981-07-31 1985-03-05 Eby Iii George A Method for reducing the duration of the common cold
US5095035A (en) 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
US5409905A (en) 1981-01-05 1995-04-25 Eby, Iii; George A. Cure for commond cold
US5286748A (en) 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US4956385A (en) 1981-07-31 1990-09-11 Eby Iii George A Method for reducing the duration of the common cold
USRE33465E (en) 1981-07-31 1990-11-27 Method for reducing the duration of the common cold
GB2133691B (en) * 1983-01-21 1986-05-21 Leo Ab Smoking substitutes for nasal administration
US4686528A (en) 1984-01-31 1987-08-11 Motorola, Inc. Method of encoding and decoding data signals
US4758439A (en) 1984-06-11 1988-07-19 Godfrey Science & Design, Inc. Flavor of zinc supplements for oral use
DE3431727A1 (en) * 1984-08-29 1986-03-13 Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen Nasal spray for coryza and influenza with a content of zinc gluconate
US4724231A (en) * 1985-04-16 1988-02-09 Nastech Pharmaceutical, Inc. Nasel compositions containing vitamin B12
JPS63101318A (en) * 1986-10-16 1988-05-06 Toko Yakuhin Kogyo Kk Collunarium
US4778810A (en) * 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
EP0296227A1 (en) * 1987-01-08 1988-12-28 Nastech Pharmaceutical Company, Inc. Nasal delivery of amino acids
JPS63174924A (en) * 1987-01-14 1988-07-19 Toko Yakuhin Kogyo Kk Ointment base and ointment
ATE84968T1 (en) * 1987-11-13 1993-02-15 Asta Medica Ag MEDICATIONS CONTAINING AZELASTINE FOR NOSE AND/OR EYE USE.
US4885287A (en) 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
GB8902300D0 (en) 1989-02-02 1989-03-22 Bryce Smith Derek Antirhinoviral preparations
JPH0678245B2 (en) * 1989-07-04 1994-10-05 東興薬品工業株式会社 Influenza vaccine gel formulation for nasal spray administration
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5785054A (en) * 1989-06-06 1998-07-28 Kelly; Patrick D. Genital lubricant with zinc salt, labelled as anti-viral agent
GB8916625D0 (en) * 1989-07-20 1989-09-06 Bryce Smith Derek Respiratory tract spray preparations
IL101056A (en) * 1992-02-24 1997-03-18 Res & Dev Co Ltd Composition for nasal treatment
GB9218834D0 (en) * 1992-09-05 1992-10-21 Procter & Gamble Nasal spray products
US5760085A (en) * 1993-04-30 1998-06-02 The Procter & Gamble Company Topical aromatic releasing compositions
JPH07316038A (en) * 1994-05-23 1995-12-05 Ikeda Mohandou:Kk Medicine composition for mucosal administration
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5733535A (en) * 1995-10-25 1998-03-31 The Procter & Gamble Co. Topical compositions containing N-acetylcysteine and odor masking materials
US6344210B2 (en) * 1996-05-10 2002-02-05 Charles A. Fust Composition for freshening nostrils and sinus cavities
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
US6929800B2 (en) * 2001-08-06 2005-08-16 Abdul Rasoul Salman Nasal passage cleaning composition
WO2004024225A1 (en) * 2002-09-16 2004-03-25 Zicam, Llc. System and method for delivering a composition to the nasal membrane
CN101198687A (en) * 2005-06-18 2008-06-11 宝洁公司 Cleansing bar compositions comprising a high level of water

Also Published As

Publication number Publication date
JP2008013572A (en) 2008-01-24
BR9906758A (en) 2002-01-15
US20040109895A1 (en) 2004-06-10
US6080783A (en) 2000-06-27
EP1039896A4 (en) 2007-08-15
US7989003B2 (en) 2011-08-02
CN1293869C (en) 2007-01-10
CN1287486A (en) 2001-03-14
US7348360B2 (en) 2008-03-25
AU5907599A (en) 2000-03-21
KR100439323B1 (en) 2004-07-07
KR20010031680A (en) 2001-04-16
CA2308513C (en) 2005-01-04
US6673835B1 (en) 2004-01-06
WO2000012081A1 (en) 2000-03-09
US20050118243A1 (en) 2005-06-02
US6365624B1 (en) 2002-04-02
JP2002523453A (en) 2002-07-30
AU774410B2 (en) 2004-06-24
US20070265337A1 (en) 2007-11-15
US20110077296A1 (en) 2011-03-31
EP1039896A1 (en) 2000-10-04
US20020032231A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
CA2308513A1 (en) Method and composition for delivering zinc to the nasal membrane
AU2977695A (en) Compositions for applying active substances to or through the skin
CA2204626A1 (en) Hydrocarbyl containing coatings, compositions and methods of use
AU5743996A (en) Compositions and methods for nucleic acid delivery to the lu ng
IL122783A0 (en) Cell adhesion inhibitors and pharmaceutical compositions containing the same
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
AU1663195A (en) Liquid pharmaceutical compositions comprising thyroid hormones
EP0684044A3 (en) Composition consisting of a dendrimer and an active substance.
AU571372B2 (en) Gel based delivery of active substances
CA2307607A1 (en) Powdery nasal compositions
CA2154424A1 (en) 1-phenyl-3-dimethylaminopropane compounds having a pharmaceutical effect
AU9021298A (en) Agmatine as a treatment for neuropathic pain
WO1998018500A8 (en) Improvements in or relating to diagnostic/therapeutic agents
AU3761495A (en) Method for forming and packaging iontophoretic drug delivery patches and the like to increase stability and shelf-life
CA2271944A1 (en) Formulation for electrically assisted delivery of lidocaine and epinephrine
HUP9900795A3 (en) Sinergetical fungicide composition containing fenazaquine and amide compound as active ingredients and use thereof
AU1766595A (en) Biologically active substance-secreting hybrid gel
AU2380595A (en) Biologically active composition
AU6372496A (en) Absorbent material, absorbent body made of the material, and method for the preparation of the material
AU696769B2 (en) Mouth moistener for the relief of dry mouth condition
AU7277598A (en) Energy delivery of catheter and method for the use thereof
EP1133979A3 (en) Use of specific fatty compounds for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon
WO1998053850A3 (en) Compositions and means for the treatment of burns and other cutaneous traumas
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
BG103262A (en) Antimycotic gel with high degree of active substance release

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130904